微创开胸术与常规胸骨正中切开术用于二尖瓣修复:一项随机临床试验
该多中心优效性随机试验纳入330例退行性二尖瓣反流患者,比较微创开胸术与胸骨正中切开术行二尖瓣修复的安全性与有效性。术后12周SF-36躯体功能评分变化组间差异为0.68(95%CI,-1.89至3.26),微创开胸术未优于胸骨正中切开术;两组瓣膜修复率约96%,1年安全结局相似。
要点
- 术后12周SF-36躯体功能T评分变化组间差异为0.68(95%CI,-1.89至3.26),微创开胸术未优于胸骨正中切开术。
- 两组瓣膜修复率约96%,1年超声心动图显示92%的患者二尖瓣反流为无或轻度,组间无差异。
- 1年复合安全结局:微创开胸术组5.4%(9/166) vs 胸骨正中切开术组6.1%(10/163)。
核心结论
- 微创开胸术在术后12周躯体功能恢复方面不优于胸骨正中切开术。
- 微创开胸术可获得高比例和高质量的瓣膜修复,1年安全结局与胸骨正中切开术相似。
- 结果可为共享决策和治疗指南提供证据。
研究设计与样本
- 实用性、多中心、优效性随机临床试验,在英国10家三级医疗中心开展。
- 纳入因退行性二尖瓣反流接受二尖瓣修复手术的成人患者。
- 采用1:1隐蔽分配随机,由专家外科医生实施微创开胸术或胸骨正中切开术二尖瓣修复。
- 2016年11月至2021年1月共随机330例参与者,平均年龄67岁,女性100例(30%);166例分配至微创开胸术组,164例分配至胸骨正中切开术组。
- 309例接受了手术,294例报告了主要结局。
主要发现
- 术后12周SF-36第2版躯体功能量表评分较基线的变化,组间平均差异为0.68(95%CI,-1.89至3.26)。
- 两组瓣膜修复率约96%,相似。
- 1年超声心动图显示92%的参与者二尖瓣反流严重程度为无或轻度,组间无差异。
- 1年复合安全结局发生率:微创开胸术组5.4%(9/166) vs 胸骨正中切开术组6.1%(10/163)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The safety and effectiveness of mitral valve repair via thoracoscopically-guided minithoracotomy (minithoracotomy) compared with median sternotomy (sternotomy) in patients with degenerative mitral valve regurgitation is uncertain. OBJECTIVE: To compare the safety and effectiveness of minithoracotomy vs sternotomy mitral valve repair in a randomized trial. DESIGN, SETTING, AND PARTICIPANTS: A pragmatic, multicenter, superiority, randomized clinical trial in 10 tertiary care institutions in the UK. Participants were adults with degenerative mitral regurgitation undergoing mitral valve repair surgery. INTERVENTIONS: Participants were randomized 1:1 with concealed allocation to receive either minithoracotomy or sternotomy mitral valve repair performed by an expert surgeon. MAIN OUTCOMES AND MEASURES: The primary outcome was physical functioning and associated return to usual activities measured by change from baseline in the 36-Item Short Form Health Survey (SF-36) version 2 physical functioning scale 12 weeks after the index surgery, assessed by an independent researcher masked to the intervention. Secondary outcomes included recurrent mitral regurgitation grade, physical activity, and quality of life. The prespecified safety outcomes included death, repeat mitral valve surgery, or heart failure hospitalization up to 1 year. RESULTS: Between November 2016 and January 2021, 330 participants were randomized (mean age, 67 years, 100 female [30%]); 166 were allocated to minithoracotomy and 164 allocated to sternotomy, of whom 309 underwent surgery and 294 reported the primary outcome. At 12 weeks, the mean between-group difference in the change in the SF-36 physical function T score was 0.68 (95% CI, -1.89 to 3.26). Valve repair rates (≈ 96%) were similar in both groups. Echocardiography demonstrated mitral regurgitation severity as none or mild for 92% of participants at 1 year with no difference between groups. The composite safety outcome occurred in 5.4% (9 of 166) of patients undergoing minithoracotomy and 6.1% (10 of 163) undergoing sternotomy at 1 year. CONCLUSIONS AND RELEVANCE: Minithoracotomy is not superior to sternotomy in recovery of physical function at 12 weeks. Minithoracotomy achieves high rates and quality of valve repair and has similar safety outcomes at 1 year to sternotomy. The results provide evidence to inform shared decision-making and treatment guidelines. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN13930454.
引用
- Akowuah EF, Maier RH, Hancock HC, et al. Minithoracotomy vs Conventional Sternotomy for Mitral Valve Repair: A Randomized Clinical Trial. JAMA. 2023. PMID: 37314276. doi:10.1001/jama.2023.7800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。